Zhang et al reported that compared with control patients, patients who received albumin infusion therapy survived significantly longer and had a shorter hospital stay.[27] Another study highlighted the impact of albumin infusion on hypercoagulability in patients hospitalized with SARS-CoV-2 infection.[28] Twenty-nine pneumonia patients with COVID-19 (D-dimer levels > 1 μg/mL and serum albumin < 3.5 g/dL) were divided into 2 groups. This evidence concerns the gene ALB and pneumonia.